Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 5/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10265823 | 0.87 | CNR2 (0.49) | CNR2MAPTELANEHSD17B10LTA4H | |
| SCHEMBL218308 | 0.81 | CNR2 (0.48) | CNR2ALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL13531293 | 0.77 | SMN1; SMN2 (0.43) | CNR2MAPTHSD17B10KDM4ENPC1 | |
| SCHEMBL2736604 | 0.73 | CNR2 (0.48) | CNR2ALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL346909 | 0.72 | NPC1 (0.50) | CNR2MAPTELANEHSD17B10NPSR1 | |
| SCHEMBL10668448 | 0.70 | NPC1 (0.49) | CNR2MAPTELANEHSD17B10NPSR1 | |
| SCHEMBL2736483 | 0.70 | CNR2 (0.71) | CNR2MAPTLTA4HKCNH2KDM4E | |
| SCHEMBL9499089 | 0.68 | NPC1 (0.52) | CNR2MAPTHSD17B10NPSR1LTA4H | |
| SCHEMBL28441097 | 0.67 | NPC1 (0.54) | CNR2MAPTNPSR1KDM4ENPC1 | |
| SCHEMBL14542334 | 0.67 | LTA4H (0.54) | CNR2MAPTNPSR1LTA4HKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088924-B2 | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor | SHIONOGI & CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | TADA YUKIO | 2010-04-01 | — | — | US | disclosed |
| US-20080312292-A1 | Antipruritics | YASUI KIYOSHI | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | CNR2, CNR1, NPY2R | CNR2 1/4885MAPT 4074/4885ELANE 4607/4885 |
| US-20080312292-A1 | Antipruritics | CNR1, CNR2, OPRL1 | CNR2 2/4885MAPT 3393/4885ELANE 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.